Obesity Clinical Trial
Official title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR
Verified date | April 2016 |
Source | Orexigen Therapeutics, Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and obese subjects who are at a higher risk of having these events because they have diabetes and/or other cardiovascular risk factors.
Status | Terminated |
Enrollment | 8910 |
Est. completion date | August 2015 |
Est. primary completion date | August 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 45 Years and older |
Eligibility |
Inclusion Criteria: 1. =50 years of age (women) or =45 years of age (men) 2. Body mass index (BMI) =27 kg/m2 and =50 kg/m2 3. Waist circumference =88 cm (women) or =102 cm (men) 4. At increased risk of adverse cardiovascular outcomes: - Cardiovascular disease (confirmed diagnosis or at high likelihood of cardiovascular disease) with at least one of the following: - History of documented myocardial infarction >3 months prior to screening - History of coronary revascularization - History of carotid or peripheral revascularization - Angina with ischemic changes (resting ECG), ECG changes on a graded exercise test (GXT), or positive cardiac imaging study - Ankle brachial index <0.9 (by simple palpation) within prior 2 years - =50% stenosis of a coronary, carotid, or lower extremity artery within prior 2 years AND/OR - Type 2 diabetes mellitus with at least 2 of the following: - Hypertension (controlled with or without pharmacotherapy at <145/95 mm Hg) - Dyslipidemia requiring pharmacotherapy - Documented low HDL cholesterol (<50 mg/dL in women or <40 mg/dL in men) within prior 12 months - Current tobacco smoker Exclusion Criteria: 1. Myocardial infarction within 3 months prior to screening 2. Angina pectoris Grade III or IV as per the Canadian Cardiovascular Society grading scheme 3. Clinical history of cerebrovascular disease (stroke) 4. History of tachyarrhythmia other than sinus tachycardia 5. Planned bariatric surgery, cardiac surgery, or coronary angioplasty 6. History of seizures (including febrile seizures), cranial trauma, or other conditions that predispose the subject to seizures 7. History of mania or current diagnosis of active psychosis, active bulimia or anorexia nervosa (binge eating disorder is not exclusionary) 8. Any condition with life expectancy anticipated to be less than 4 years (e.g., congestive heart failure NYHA Class 3 or 4) |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Orexigen Therapeutics, Inc |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With a Confirmed Occurrence of Major Adverse Cardiovascular Event (MACE) | The primary endpoint is the time from randomization to the first confirmed occurrence of any event within the primary MACE composite (defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke). Due to early termination of the study, pre-planned 50% interim analysis is considered the primary analysis for outcome measures. The pre-planned 50% interim analysis was conducted when 50% of the total planned MACE were observed. | Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up | |
Secondary | Percentage of Participants With a Confirmed Occurrence of Cardiovascular Death, Nonfatal Myocardial Infarction, Nonfatal Stroke, or Nonfatal Unstable Angina Requiring Hospitalization | Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. | Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up | |
Secondary | Percentage of Participants With a Confirmed Occurrence of Cardiovascular Death (Including Fatal Myocardial Infarction, Fatal Stroke) | Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. | Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up | |
Secondary | Percentage of Participants With a Confirmed Occurrence of Myocardial Infarction (Nonfatal or Fatal) | Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. | Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up | |
Secondary | Percentage of Participants With a Confirmed Occurrence of Stroke (Nonfatal or Fatal) | Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. | Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |